CClinicalTrials.gg
TerminatedNCT02935569Updated Feb 28, 2017

Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy

An interventional study of Compression HeadBand in Alopecia, sponsored by Michael Milano, MD,PhD. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by Michael Milano, MD,PhD · Not applicable, Interventional, and Supportive care

Why this study was terminated
Results with 4 subjects suggest a redesign of Compression system is required.
Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study hypothesizes that in patients undergoing whole brain radiotherapy, a compression headband will decrease the percentage of patients with significant hair loss following radiation.

Read the detailed description

This is a pilot feasibility study. The primary objective of this study is to seek preliminary information to answer the following question:

  1. Does a compression headband, placed only at the time of irradiation, reduce the incidence of significant hair loss after whole brain radiation, as compared to historical controls?

    This study will also seek to answer these secondary questions:

  2. Is a temporary compression headband well tolerated in patients undergoing whole brain radiation?
  3. If a portion of patients do have significant hair loss after radiation in spite of compression banding, what is the timing of hair regrowth?
  4. In normal volunteers, does a compression headband cause acute hypoxia in the scalp, as measured by a transcutaneous oxygen pressure monitor, and, if so, to what degree?
02

Conditions studied

  • Alopecia

Browse trials for

Keywords

  • Alopecia
  • Radiotherapy
03

In context

Alopecia

609 studies on the registry are indexed under Alopecia; 131 are open to participants now.

This study's enrollment of 4 is below the median of 45 across 513 interventional studies indexed under Alopecia.

Browse Alopecia studies →

Lead sponsor

This is the only study on the registry with Michael Milano, MD,PhD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age greater than or equal to 18 years old.
  • Undergoing whole brain radiation therapy, using lateral opposed fields
  • Total planned radiation prescription dose between 30 Gy and 37.5 Gy in 10 to 15 treatments.

Exclusion criteria

Exclusion Criteria:

  • Current complete or near-complete alopecia (natural or chemotherapy-induced)
  • Concurrent or sequential chemotherapy with an agent known to commonly cause alopecia (Adriamycin, Cytoxan, Ifosfamide, Taxol (greater than 50 mg/m2), or Vincristine).
  • Previous Radiation to the Scalp
  • Any active dermatologic disease affecting the scalp, or temporal arteritis
  • History of severe headaches.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Compression Headband

    a compression headband, placed only at the time of irradiation

    Device: Compression HeadBand

Interventions

  • DeviceCompression HeadBand

    * commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1" x 18" x .025") with Velcro adhesion * Plastics disks, hollow (3.5 cm diameter, by 1 cm height) Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery.

06

What researchers measure

Primary outcomes

  1. Change in Hair loss defined as grade 1 (thinning or patchy) or grade 2 (complete) alopecia (hair loss), as per Common Toxicity Criteria for Adverse Effects (CTCAE) version 3

    The primary outcome of this study will be the presence of "significant hair loss" by 6 weeks after the completion of whole brain radiation. This will be defined as grade 1 (thinning or patchy) or grade 2 (complete) alopecia (hair loss), as per Common Toxicity Criteria for Adverse Effects (CTCAE) version 3. The amount of hair loss will be evaluated at the following time points. * Before whole brain radiation * six weeks following radiation

    Time frame: baseline to 6 weeks

Secondary outcomes

  1. Temporary compression headband side effects (Nausea, Headache, Redness, Tingling) in patients undergoing whole brain radiation

    Does a temporary compression headband cause side effects in patients undergoing whole brain ? Nausea? Headache? Redness? Tingling?

    Time frame: 6 weeks

  2. Timing of hair regrowth

    If a portion of patients do have significant hair loss after radiation in spite of compression banding, what is the timing of hair regrowth?

    Time frame: one year

  3. Acute hypoxia in the scalp of normal volunteers caused by compression headband (if present, to what degree?) as measured by a transcutaneous oxygen pressure monitor

    In normal volunteers, does a compression headband cause acute hypoxia in the scalp, as measured by a transcutaneous oxygen pressure monitor, and, if so, to what degree?

    Time frame: 1 hour

07

Study locations

1 site
  • Dept. of Radiation Oncology, University of Rochester, Med Center
    Rochester, New York 14642, United States
08

References and documents

Individual participant data

Plan to share: Yes — Researchers can contact the PI to obtain IPD with collaboration.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02935569
Lead sponsor
Michael Milano, MD,PhD
Responsible party
Michael Milano, MD,PhD (Assoc Professor, Radiation Oncology, University of Rochester) — Sponsor-investigator
First posted
Oct 17, 2016
Start date
May 2012
Primary completion
Aug 2014
Completion
Aug 2014
Last update
Feb 28, 2017

Study contacts

Michael Milano, MD, PhD
principal investigator · University of Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion